fbpx
QQQ
+ 0.00
271.64
+ 0%
DIA
+ 0.00
265.46
+ 0%
SPY
+ 0.00
326.70
+ 0%
TLT
+ 0.00
160.70
+ 0%
GLD
+ 0.00
176.14
+ 0%

FDA Grants GW Pharmaceuticals Priority Review For Cannabidiol Drug In Seizure Condition

April 1, 2020 12:20 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

A drug from GW Pharmaceuticals plc (NASDAQ:GWPH) targeting a cause of genetic epilepsy has received Priority Review status from the U.S. Food and Drug Administration. 

The Cambridge, U.K.-based company and its subsidiary Greenwich Biosciences Inc. confirmed Tuesday that their new drug application for the use of Epidiolex — cannabidiol — CV will have a review time of about six months instead of the FDA's typical 10. 

This status is usually granted to therapeutics that have the potential of treating an illness that doesn’t have an existing therapy. 

The GW drug is focused on treating seizures related to Tuberous Sclerosis Complex, or TSC, a rare genetic condition that causes the development of usually benign tumors in vital organs. It's considered a primary cause of genetic epilepsy, according to the company. 

Per the Prescription Drug User Fee Act, the FDA review of the EPIDIOLEX supplemental new drug application has a goal finalization date of July 31, according to GW.

Leer en Español: Epidiolex, la Droga con CBD para Epilepsia, se Abre Camino Legal

Epidiolex oral solution, CV, has already been authorized for treating seizures connected with two rare forms of childhood-onset epilepsy, Lennox-Gastaut syndrome, and Dravet syndrome.

“We are pleased with the FDA’s acceptance of our EPIDIOLEX sNDA filing with Priority Review, an action that underscores the unmet need for new treatment options for patients with TSC, a rare and severe childhood-onset disease,” GW Chief Executive Officer Justin Gover said in a statement.

More than 60% of individuals with TSC do not achieve seizure control with standard anti-epileptic drug treatments, he said. 

"Today’s news is therefore important for TSC patients and their clinicians, and we look forward to working with the FDA during the review process to expand the EPIDIOLEX product label for use in TSC,” he added.

GW Pharma shares were trading 0.33% higher at $87.86 at the time of publication Wednesday.

Related Links:

GW Pharma Obtains Exclusive UK Commercialization Rights To Sativex From Bayer

GW Pharma's Epidiolex Label Expansion, EU Launch Key Growth Drivers In 2020

Photo courtesy of GW Pharmaceuticals. 


Related Articles

Real Brands Closes Merger With Canadian American Standard Hemp

Real Brands Inc. (OTCPK: RLBD) confirmed Tuesday, it has finalized the acquisition of Canadian American Standard Hemp Inc. read more

Turning Point Brands Backs Cannabinoid Company Dosist With $15M

Turning Point Brands Inc. (NYSE: TPB) agreed to invest $15 million in Dosist, a cannabinoid company. The two companies opted to co-create a new CBD brand featuring thc-free products.  read more

The Week In Cannabis: Stocks Outperform, Michigan Shapes Up As New Leader, Celeb Brands Get Hot

Cannabis stocks traded up in a relatively slow news week, where celebrity brands grabbed headlines. read more

Working Moms Are Keeping CBD In The Medicine Cabinet

This article was originally published on Cannabis & Tech Today, and appears here with permission. Parenting is never an easy task — and that’s been true since the beginning of time. Raising a kid isn’t a job that can be taken lightly, and that only adds more stress to the situation. read more

CBD Oils 101: The Difference Between Full-Spectrum, Broad-Spectrum And Isolate

This article is originally published on Sunday Scaries. read more